TAO falls below $150

Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing.

Eton Pharmaceuticals, Inc. has signed a licensing agreement to successfully acquire the exclusive U.S. marketing rights for Hemangeol oral solution from Pierre Fabre Medicament Sas.

While actively promoting a stock buyback program to narrow the net asset value discount, ProCap Financial recently completed a strategic acquisition of 450 bitcoins.

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), healthcare giant Humana stated that its GAAP-based earnings per share (EPS) guidance for fiscal year 2026 may be adjusted due to the company's ongoing value creation plan and other strategic initiatives.